Artgen's IFRS net profit for 2024 amounted to ₽241.2 million, up 23.9% from ₽194.7 million in the previous year. Revenue rose 10.9% to ₽1.52 billion against ₽1.37 billion a year earlier.

Artgen's RAS net profit for 2024 amounted to ₽265.45 million, up 8.5% from ₽244.62 million in the previous year. Revenue rose 61.7% to ₽119.86 million against ₽74.14 million a year earlier.

NexTgen has received approval from the Ministry of Health to conduct Phase III clinical trials of the gene therapy drug Neovasculgen® for the treatment of diabetic foot syndrome. Results of Phase I and II confirmed that the drug injection into the affected tissues reduces the healing time of ulcer defects and improves the quality of tissue regeneration. In P...

Nextgen has started preclinical studies of the efficacy of a gene therapy drug for the treatment of androgenic alopecia. It is the expansion of indications for the use of the world's first genotherapeutic drug Neovasculgen with the mechanism of action therapeutic angiogenesis (therapeutic vascular growth).